Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025.

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to ... UCCD study in patients with moderate-to-severe ulcerative colitis (UC) and Crohn's disease suggest a "best ...

Teva Pharmaceutical (NYSE:TEVA) and Alvotech (NASDAQ:ALVO) have launched their biosimilar targeting Johnson & Johnson’s (NYSE:JNJ) blockbuster arthritis therapy Stelara (ustekinumab) in the U.S. weeks ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY ... for the treatment of moderate-to-severe ulcerative colitis and Crohn’s disease. These results were shared in two oral presentations at the ...

We make things happen." On the branded drug Duvakitug, which Teva is developing with Sanofi, for the treatment of ulcerative colitis and Crohn's disease, and which surprised in December with strong ...

According to the National Institutes of Health, between 600,000 and 900,000 Americans have ulcerative colitis, a chronic ...

ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis. This is the second biosimilar now available in the U.S. market under the Teva and Alvotech strategic partnership.

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). The product is indicated for the ...

The human gut is home to trillions of bacteria that play vital roles in digestion, immunity, and overall health.